CN1306958C - 用于免疫受损人群的糖结合物疫苗 - Google Patents

用于免疫受损人群的糖结合物疫苗 Download PDF

Info

Publication number
CN1306958C
CN1306958C CNB028184238A CN02818423A CN1306958C CN 1306958 C CN1306958 C CN 1306958C CN B028184238 A CNB028184238 A CN B028184238A CN 02818423 A CN02818423 A CN 02818423A CN 1306958 C CN1306958 C CN 1306958C
Authority
CN
China
Prior art keywords
type
vaccine
antigens
immunologic function
involved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB028184238A
Other languages
English (en)
Chinese (zh)
Other versions
CN1638794A (zh
Inventor
A·I·法托姆
R·B·纳索
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaxart Inc
Original Assignee
Nabi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabi Inc filed Critical Nabi Inc
Publication of CN1638794A publication Critical patent/CN1638794A/zh
Application granted granted Critical
Publication of CN1306958C publication Critical patent/CN1306958C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CNB028184238A 2001-09-19 2002-09-19 用于免疫受损人群的糖结合物疫苗 Expired - Lifetime CN1306958C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/955,585 2001-09-19
US09/955,585 US20030113350A1 (en) 2001-09-19 2001-09-19 Glycoconjugate vaccines for use in immune-compromised populations

Publications (2)

Publication Number Publication Date
CN1638794A CN1638794A (zh) 2005-07-13
CN1306958C true CN1306958C (zh) 2007-03-28

Family

ID=25497036

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028184238A Expired - Lifetime CN1306958C (zh) 2001-09-19 2002-09-19 用于免疫受损人群的糖结合物疫苗

Country Status (11)

Country Link
US (2) US20030113350A1 (https=)
EP (1) EP1427442A4 (https=)
JP (2) JP2005515237A (https=)
KR (3) KR20040070331A (https=)
CN (1) CN1306958C (https=)
CA (1) CA2460749C (https=)
EA (1) EA006602B1 (https=)
MX (1) MXPA04002624A (https=)
NZ (1) NZ548453A (https=)
WO (1) WO2003061558A2 (https=)
ZA (1) ZA200402185B (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100217772B1 (ko) * 1996-09-03 1999-09-01 최진호 조명기기의 램프 과열방지 장치 및 방법
US20020092987A1 (en) * 1998-09-05 2002-07-18 Taehee Cho Photo detect device using quantum dots and materialization method thereof
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
PL229487B1 (pl) 2002-11-12 2018-07-31 Brigham & Womens Hospital Inc Kompozycja zawierająca polimer β-1,6-glukozaminy, kompozycja zawierająca przeciwciało, kompozycja farmaceutyczna, sposób wytwarzania wyodrębnionego polisacharydu, sposób identyfikacji obecności deacetylowanej poli-N-acetyloglukozaminy (dPNAG) i/ lub poli-N-acetyloglukozaminy (PNAG), wyodrębniony polisacharyd do zastosowania w leczeniu lub profilaktyce zakażenia, wyodrębniony polisacharyd do zastosowania do wytwarzania przeciwciał, w tym przeciwciał monoklonalnych, wyodrębniony polisacharyd do zastosowania w identyfikacji przeciwciała monoklonalnego
AU2003298770A1 (en) * 2002-12-02 2004-06-23 Biosynexus Inc Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines
CA2517439C (en) 2003-03-07 2013-07-23 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
NZ553776A (en) * 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.
AU2011265368B9 (en) * 2004-09-22 2012-11-29 Biosynexus Incorporated Immunogenic composition
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
WO2006076058A1 (en) * 2005-01-10 2006-07-20 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
FR2884830A1 (fr) 2005-04-25 2006-10-27 Sanofi Pasteur Sa Procede de production de souches de staphylococcus aureus surproductrices
ES2372537T3 (es) * 2005-07-29 2012-01-23 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services Exotoxinas de pseudomonas mutadas con antigenicidad reducida.
EP2476433A1 (en) * 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogenic composition
FR2899110A1 (fr) * 2006-03-31 2007-10-05 Sanofi Pasteur Sa Polysaccharides capsulaires de type 5 et de type 8 des souches surproductrices de staphylococcus aureus
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
JP5658564B2 (ja) * 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
CN102159540B (zh) 2008-07-21 2015-08-12 布赖汉姆妇女医院 与合成的β-1,6葡糖胺寡糖相关的方法和组合物
WO2010014304A1 (en) * 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
HUE026855T2 (en) 2009-04-03 2016-07-28 Univ Chicago Compositions and methods related to protein a (spa) variants
SA110310528B1 (ar) 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
SG10201406432RA (en) 2009-06-22 2014-11-27 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
BR112012009014B8 (pt) 2009-09-30 2022-10-04 Novartis Ag Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica
HUE034251T2 (en) 2009-10-30 2018-02-28 Glaxosmithkline Biologicals Sa Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
EP2525800B1 (en) * 2010-01-19 2018-07-04 Universitätsklinikum Freiburg Enterococcal cell wall components and antibacterial use thereof
CA2803298C (en) 2010-07-02 2020-07-14 The University Of Chicago Compositions and methods related to protein a (spa) variants
CN102539704A (zh) * 2010-12-13 2012-07-04 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102565336A (zh) * 2010-12-13 2012-07-11 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102565354A (zh) * 2010-12-13 2012-07-11 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102539708A (zh) * 2010-12-13 2012-07-04 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102565332A (zh) * 2010-12-13 2012-07-11 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102539726A (zh) * 2010-12-13 2012-07-04 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
CN102539702A (zh) * 2010-12-13 2012-07-04 苏州艾杰生物科技有限公司 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
US9777076B2 (en) 2012-07-16 2017-10-03 Pfizer Inc. Saccharides and uses thereof
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
AU2015359503B2 (en) 2014-12-10 2019-05-09 Glaxosmithkline Biologicals Sa Method of treatment
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
US12397014B2 (en) 2019-02-05 2025-08-26 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
US12514914B2 (en) 2019-05-14 2026-01-06 The University Of Chicago Methods and compositions comprising Staphylococcus protein a (SpA) variants
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CA3152520A1 (en) * 2019-08-27 2021-03-04 OneBioPharma, Inc. Antimicrobial vaccine compositions
CN114929750B (zh) 2019-09-13 2024-11-22 芝加哥大学 用于治疗葡萄球菌感染的方法和组合物
US20260007731A1 (en) * 2022-01-05 2026-01-08 Bluewillow Biologics, Inc. Intranasal polysaccharide conjugate nanomulsion vaccines and methods of using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747024A (en) * 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Effect of conjugation methodology, carrier protein, andadjuvants on the immune response to Staphylococcus aureuscapsular polysaccharides Fattom,.A et al,Vaccine,Vol.13 No.14 1995 *
Safety and immunogenicity of Staphylococcus aureus type 5capsular polysaccharide-Pseudomonas aeruginosarecombinant exoprotein A conjugate vaccine in patients onhemodialysis Welch,.P.G et al,J.Am.Soc.Nephrol.,Vol.7 No.2 1996 *

Also Published As

Publication number Publication date
WO2003061558A3 (en) 2003-09-12
NZ548453A (en) 2007-07-27
EP1427442A2 (en) 2004-06-16
US20030113350A1 (en) 2003-06-19
US7449189B2 (en) 2008-11-11
JP2010265293A (ja) 2010-11-25
EA200400448A1 (ru) 2004-12-30
ZA200402185B (en) 2005-06-29
KR101090529B1 (ko) 2011-12-08
KR20040070331A (ko) 2004-08-07
CA2460749C (en) 2012-10-23
CA2460749A1 (en) 2003-07-31
WO2003061558A9 (en) 2004-06-10
KR20080089527A (ko) 2008-10-06
MXPA04002624A (es) 2005-02-17
KR20100044265A (ko) 2010-04-29
KR101214766B1 (ko) 2012-12-24
EP1427442A4 (en) 2006-06-21
WO2003061558A2 (en) 2003-07-31
EA006602B1 (ru) 2006-02-24
JP2005515237A (ja) 2005-05-26
CN1638794A (zh) 2005-07-13
US20060188518A1 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
CN1306958C (zh) 用于免疫受损人群的糖结合物疫苗
Wessels et al. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine
Devi et al. Antibodies to poly [(2----8)-alpha-N-acetylneuraminic acid] and poly [(2----9)-alpha-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1.
AU2005316864B2 (en) Glycoconjugate vaccines containing peptidoglycan
EA037500B1 (ru) Способы и композиции для иммунной защиты против внекишечной патогенной e. coli
JP2009227680A (ja) 腸球菌抗原およびワクチン
Bundle et al. Design of a Candida albicans disaccharide conjugate vaccine by reverse engineering a protective monoclonal antibody
JP2631035B2 (ja) 多糖類−タンパク質複合体
US20120231086A1 (en) Protein matrix vaccines of improved immunogenicity
Cross Hit ‘em where it hurts: gram-negative bacterial lipopolysaccharide as a vaccine target
EP4512419A1 (en) Polyvalent pneumococcal polysaccharide conjugate vaccine component and application thereof
WO2014195880A1 (en) An isolated immunogenic bacterial antigen and its use in the prevention and treatment of infections caused by gram-negative bacteria
Cryz Jr et al. Synthesis and characterization of Escherichia coli O18 O-polysaccharide conjugate vaccines
Salo et al. Salicylate-enhanced exposure of Klebsiella pneumoniae subcapsular components
AU2002365253B2 (en) Glycoconjugate vaccines for use in immune-compromised populations
CN101443454A (zh) 多价脑膜炎球菌衍生化的多糖-蛋白质缀合物和疫苗
Henriksen et al. Vaccination with Protein‐Conjugated and Native Type 3 Capsular Polysaccharide in an Ethanol‐Fed Rat Model of Pneumococcal Pneumonia
Pon et al. Carbohydrate‐Based Antibacterial Vaccines
NZ531647A (en) Glycoconjugate vaccines for use in immune-compromised populations against Staphylococcal and Enterococcal infections
RU2780425C2 (ru) Композиции neisseria meningitidis и способы
AU2002365253A1 (en) Glycoconjugate vaccines for use in immune-compromised populations
Czerkinsky Physical and Chemical Characterization and Immunologic Properties of Salmonella enterica Serovar Typhi Capsular Polysaccharide-Diphtheria Toxoid Conjugates
Liao et al. Characterization of a human monoclonal immunoglobulin M (IgM) antibody (IgMBEN) specific for Vi capsular polysaccharide of Salmonella typhi
D'Cor et al. Safety and Immunogenicity of a Cholera Conjugate Vaccine in Healthy South Korean Adults: A Phase 1 Dose-Escalation Trial
Byrd Development of conjugate vaccines to protect pigs against swine pleuropneumonia induced by Actinobacillus pleuropneumoniae

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: GLAXOSMITHKLINE BIOLOGICALS COMPANY

Free format text: FORMER OWNER: NABI

Effective date: 20100809

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: MARYLAND STATE, USA TO: RICKSON SARTRE, BELGIUM

TR01 Transfer of patent right

Effective date of registration: 20100809

Address after: Belgium Sutter Rixon

Patentee after: NABI BIOPHARMACEUTICALS

Address before: American Maryland

Patentee before: NABI Biopharmaceuticals

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20070328